SCHEMBL23827366

SCHEMBL23827366

Nc1ccc(OCC(O)C(=O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
APP P05067 1/20 0.42
CYP1A2 P05177 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
NPC1 O15118 2/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23827362 1.00 TDP1 (0.44) TDP1TSHRMAPTLMNAPOLB
SCHEMBL2731803 0.82 LMNA (0.59) LMNAL3MBTL1ADRB2ADRB1ADRB3
SCHEMBL8468149 0.82 LMNA (0.59) LMNAL3MBTL1ADRB2ADRB1ADRB3
SCHEMBL9283760 0.82 LMNA (0.59) LMNAL3MBTL1ADRB2ADRB1ADRB3
SCHEMBL5421055 0.82 LMNA (0.59) LMNAL3MBTL1ADRB2ADRB1ADRB3
SCHEMBL18990146 0.81 LDHA (0.52) TDP1TSHRMAPTLMNAPOLB
SCHEMBL1548918 0.81 PPARG (0.59) RAB9ACYP1A2PPARGPPARAALDH1A1
SCHEMBL18990145 0.81 LDHA (0.52) TDP1TSHRMAPTLMNAPOLB
SCHEMBL11451793 0.81 NR4A2 (0.47) TSHRMAPTLMNAPOLBNPSR1
SCHEMBL787523 0.80 TDP1 (0.49) TDP1TSHRMAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111171014-B Monocyclolactam compounds and uses thereof 南京圣和药业股份有限公司 2023-11-07 CN disclosed
CN-112771040-B Monocyclic lactam compounds and uses thereof 南京圣和药业股份有限公司 2022-10-18 CN disclosed
US-20220002288-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2022-01-06 US disclosed
EP-3882246-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2021-09-22 EP disclosed
CN-112771040-A Monocyclic lactam compounds and uses thereof 南京圣和药业股份有限公司 2021-05-07 CN disclosed
CN-111171014-A Monocyclic lactam compounds and uses thereof 南京圣和药业股份有限公司 2020-05-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002288-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR BPGM, IL1B, WEE1 TDP1 3885/4885TSHR 4759/4885MAPT 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.